首頁 > 市場調查報告書 > 製藥

癌症呼吸器

2030 年歐洲肺癌治療市場預測 - 區域分析 - 按治療類型、適應症和最終用戶

市場調查報告書

商品編碼

1494406

2030 年歐洲肺癌治療市場預測 - 區域分析 - 按治療類型、適應症和最終用戶

Europe Lung Cancer Therapy Market Forecast to 2030 - Regional Analysis - By Therapy Type, Indication, and End User

出版日期: 2024年03月14日 | 出版商:

The Insight Partners | 英文 92 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

2022年歐洲肺癌治療市值為991966萬美元，預計2030年將達2554874萬美元；預計2022年至2030年複合年成長率為12.6%。

政府肺癌篩檢和治療措施推動歐洲肺癌治療市場

據強生公司發表的文章稱，肺癌是全球癌症死亡的主要原因，而且通常在晚期才被發現。在早期階段，肺癌患者沒有明顯的症狀，因此，在近50%的檢測病例中，癌症已達到轉移階段。針對肺癌的嚴重性，各國政府紛紛推出鼓勵肺癌早期發現、早期篩檢、早期治療的措施。歐洲衛生聯盟推出的「戰勝癌症計畫」旨在透過專注於肺癌患者的預防、治療和照護來解決整個疾病途徑。因此，各國政府為肺癌患者的早期檢測和適當治療所採取的措施激增，推動了歐洲肺癌治療市場的成長。

歐洲肺癌治療市場概況

根據2022年6月發表在《胸腔腫瘤學雜誌》上的一篇題為「德國的肺癌」的文章，癌症是德國第二大常見死因之一，佔所有死亡的25%。男性和女性的年齡標化發生率分別為52.1%和32.7%（每10萬人），肺癌在男性中排名第二，在女性中排名第三（分別佔所有新診斷癌症的13.3%和9.4% ）。癌症診斷的平均年齡為70歲（男性）和69歲（女性）； 52% 的患者處於 IV 期。由於吸煙習慣的長期變化，自 20 世紀 90 年代以來，女性和男性的發病率趨同。目前，德國有四分之一的男性 (27.0%) 和五分之一的女性 (20.8%) 經常吸菸。

德國國家癌症計畫指定器官癌症中心（肺癌中心）、腫瘤中心和綜合癌症中心在德國提供一般腫瘤護理。截至2020年，全國79家機構、64家肺癌中心獲得認證。德國肺癌發病率的上升和肺癌中心數量的增加正在推動市場的成長。

歐洲肺癌治療市場收入及 2030 年預測（百萬美元）

歐洲肺癌治療市場細分

歐洲肺癌治療市場根據治療類型、適應症、最終用戶和國家進行細分。

根據治療類型，歐洲肺癌治療市場分為非侵入性治療和微創治療。到2022年，非侵入性細分市場將佔更大佔有率。

有跡象表明，歐洲肺癌治療市場分為非小細胞肺癌和小細胞肺癌。 2022 年，非小細胞肺癌細分市場將佔據更大佔有率。

依最終用戶分類，歐洲肺癌治療市場分為醫院、腫瘤診所、研究中心等。 2022 年，醫院領域佔最大佔有率。

根據國家/地區，歐洲肺癌治療市場分為德國、英國、法國、義大利、西班牙、俄羅斯和歐洲其他地區。 2022年，德國在歐洲肺癌治療市場佔據主導地位。

Medtronic Plc、RF Medical Co Ltd、Johnson & Johnson、Merck KGaA、Sun Pharmaceutical Industries Ltd、Bioventus Inc、Olympus Corp、Meiji Seika Pharma Co Ltd 和 Advanz Pharma Corp 是歐洲肺癌治療市場上的一些領先公司。

According to an article published by Johnson & Johnson, lung cancer is a leading cause of cancer mortality in the world, and it is generally detected in the later stages. In the initial stages, people with lung cancer show no prominent symptoms, and therefore, in almost 50% of the detected cases, cancer has already reached the metastasis stage. In response to the seriousness of this condition, governments of various countries are focusing on introducing initiatives for encouraging early detection and screening, followed by providing early treatment for lung cancer. The Beating Cancer Plan introduced by the European Health Union aims to tackle the entire disease pathway by focusing on prevention, treatment, and care of lung cancer patients. Thus, an upsurge in initiatives taken by governments for the early detection and proper treatment of lung cancer patients fuels the growth of the Europe lung cancer therapy market.

Europe Lung Cancer Therapy Market Overview

According to an article titled "Lung Cancer in Germany," published in the Journal of Thoracic Oncology in June 2022, cancer is among the second most frequent cause of death in Germany, accounting for 25% of all deaths. With an age-standardized incidence rate of 52.1% and 32.7% (per 100,000) in men and women, respectively, lung cancer ranks second in men and third in women (accounting for 13.3% and 9.4% of all newly diagnosed cancers, respectively). The average age of cancer diagnosis is 70 years (men) and 69 years (women); 52% of all patients present with stage IV. The incidence rates in women and men have converged since the 1990s because of long-term changes in smoking habits. Currently, every fourth man (27.0%) and every fifth woman (20.8%) in Germany smokes regularly.

The German National Cancer Plan designates organ cancer centers (lung cancer centers), oncology centers, and comprehensive cancer centers to offer general oncologic care in Germany. As of 2020, 64 lung cancer centers at 79 institutions were certified nationwide. Rise in the incidence of lung cancer and an increase in the number of lung cancer centers across Germany are fueling the growth of the market.

Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Million)

Europe Lung Cancer Therapy Market Segmentation

The Europe lung cancer therapy market is segmented based on therapy type, indication, end user, and country.

Based on therapy type, the Europe lung cancer therapy market is bifurcated into noninvasive and minimally invasive. The noninvasive segment held a larger share in 2022. The minimally invasive segment is further subsegmented into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others.

By indication, the Europe lung cancer therapy market is bifurcated into non-small cell lung cancer and small cell lung cancer. The non-small cell lung cancer segment held a larger share in 2022.

By end user, the Europe lung cancer therapy market is segmented into hospitals, oncology clinics, research centers, and others. The hospitals segment held the largest share in 2022.

Based on country, the Europe lung cancer therapy market is segmented into Germany, the UK, France, Italy, Spain, Russia, and the Rest of Europe. Germany dominated the Europe lung cancer therapy market in 2022.

Medtronic Plc, RF Medical Co Ltd, Johnson & Johnson, Merck KGaA, Sun Pharmaceutical Industries Ltd, Bioventus Inc, Olympus Corp, Meiji Seika Pharma Co Ltd, and Advanz Pharma Corp are some of the leading companies operating in the Europe lung cancer therapy market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Europe Lung Cancer Therapy Market, by Country

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Lung Cancer Therapy Market - Key Industry Dynamics

4.1 Market Drivers:
- 4.1.1 Increase in Cases of Lung Cancer
- 4.1.2 Government Initiatives for Screening and Treatment of Lung Cancer
4.2 Market Restraints
- 4.2.1 High Cost of Lung Cancer Therapy
4.3 Market Opportunities
- 4.3.1 Rising Number of Lung Cancer Therapy in Clinical Trials
4.4 Future Trends
- 4.4.1 Growing Demand for Targeted Therapy
4.5 Impact Analysis:

5. Lung Cancer Therapy Market - Europe Market Analysis

5.1 Europe Lung Cancer Therapy Market Revenue (US$ Mn), 2020 - 2030

6. Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

6.1 Overview
6.2 Europe Lung Cancer Therapy Market Revenue Share, by Therapy Type, 2022 & 2030 (%)
6.3 Non-Invasive Therapy
- 6.3.1 Overview
- 6.3.2 Non-Invasive Therapy: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Minimally Invasive
- 6.4.1 Overview
- 6.4.2 Minimally Invasive: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- 6.4.3 Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)

7. Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by Indication

7.1 Overview
7.2 Europe Lung Cancer Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
7.3 Non-Small Cell Lung Cancer
- 7.3.1 Overview
- 7.3.2 Non-Small Cell Lung Cancer: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Small Cell Lung Cancer
- 7.4.1 Overview
- 7.4.2 Small Cell Lung Cancer: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by End User

8.1 Overview
8.2 Europe Lung Cancer Therapy Market Revenue Share, by End User, 2022 & 2030 (%)
8.3 Hospitals
- 8.3.1 Overview
- 8.3.2 Hospitals: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Oncology Clinics
- 8.4.1 Overview
- 8.4.2 Oncology Clinics: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Research Centers
- 8.5.1 Overview
- 8.5.2 Research Centers: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Lung Cancer Therapy Market - Country Analysis

9.1.1 Europe Lung Cancer Therapy Market, by Country
- 9.1.1.1 UK
  - 9.1.1.1.1 Overview
  - 9.1.1.1.2 UK: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.1.3 UK: Europe Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.1.3.1 UK: Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.1.4 UK: Europe Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.1.5 UK: Europe Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 9.1.1.2 Germany
  - 9.1.1.2.1 Overview
  - 9.1.1.2.2 Germany: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.2.3 Germany: Europe Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.2.3.1 Germany: Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.2.4 Germany: Europe Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.2.5 Germany: Europe Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 9.1.1.3 France
  - 9.1.1.3.1 Overview
  - 9.1.1.3.2 France: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.3.3 France: Europe Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.3.3.1 France: Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.3.4 France: Europe Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.3.5 France: Europe Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 9.1.1.4 Italy
  - 9.1.1.4.1 Overview
  - 9.1.1.4.2 Italy: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.4.3 Italy: Europe Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.4.3.1 Italy: Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.4.4 Italy: Europe Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.4.5 Italy: Europe Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 9.1.1.5 Spain
  - 9.1.1.5.1 Overview
  - 9.1.1.5.2 Spain: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.5.3 Spain: Europe Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.5.3.1 Spain: Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.5.4 Spain: Europe Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.5.5 Spain: Europe Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 9.1.1.6 Russia
  - 9.1.1.6.1 Overview
  - 9.1.1.6.2 Russia: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.6.3 Russia: Europe Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.6.3.1 Russia: Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.6.4 Russia: Europe Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.6.5 Russia: Europe Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 9.1.1.7 Rest of Europe
  - 9.1.1.7.1 Overview
  - 9.1.1.7.2 Rest of Europe: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.7.3 Rest of Europe: Europe Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.7.3.1 Rest of Europe: Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.7.4 Rest of Europe: Europe Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.7.5 Rest of Europe: Europe Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)

10. Lung Cancer Therapy Market - Industry Landscape

10.1 Overview
10.2 Growth Strategies in Europe Lung Cancer Therapy Market
10.3 Inorganic Growth Strategies
- 10.3.1 Overview
10.4 Organic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Medtronic Plc
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 RF Medical Co Ltd
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Johnson & Johnson
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Merck KGaA
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Sun Pharmaceutical Industries Ltd
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Bioventus Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Olympus Corp
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Meiji Seika Pharma Co Ltd
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Advanz Pharma Corp
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms

簡介目錄圖表

List Of Tables

Table 1. Europe Lung Cancer Therapy Market Segmentation
Table 2. Europe Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 3. UK: Europe Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 4. UK: Europe Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 5. UK: Europe Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 6. UK: Europe Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 7. Germany: Europe Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 8. Germany: Europe Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 9. Germany: Europe Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 10. Germany: Europe Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 11. France: Europe Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 12. France: Europe Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 13. France: Europe Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 14. France Europe Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 15. Italy Europe Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 16. Italy: Europe Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 17. Italy: Europe Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 18. Italy: Europe Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 19. Spain: Europe Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 20. Spain: Europe Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 21. Spain: Europe Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 22. Spain: Europe Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 23. Russia: Europe Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 24. Russia: Europe Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 25. Russia: Europe Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 26. Russia: Europe Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 27. Rest of Europe: Europe Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 28. Rest of Europe: Europe Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 29. Rest of Europe: Europe Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 30. Rest of Europe: Europe Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 31. Recent Inorganic Growth Strategies in the Europe Lung Cancer Therapy Market
Table 32. Recent Organic Growth Strategies in Europe Lung Cancer Therapy Market
Table 33. Glossary of Terms, Europe Lung Cancer Therapy Market

List Of Figures

Figure 1. Europe Lung Cancer Therapy Market Segmentation, By Country
Figure 2. Europe Lung Cancer Therapy Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Europe Lung Cancer Therapy Market Revenue (US$ Mn), 2020 - 2030
Figure 5. Europe Lung Cancer Therapy Market Revenue Share, by Therapy Type, 2022 & 2030 (%)
Figure 6. Non-Invasive Therapy: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Minimally Invasive: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Europe Lung Cancer Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
Figure 9. Non-Small Cell Lung Cancer: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Small Cell Lung Cancer: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Europe Lung Cancer Therapy Market Revenue Share, End User, 2022 & 2030 (%)
Figure 12. Hospitals: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Oncology Clinics: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Research Centers: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Europe Lung Cancer Therapy Market, by Key Country - Revenue, 2022 (US$ Million)
Figure 17. Europe Lung Cancer Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 18. UK: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 19. Germany: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 20. France: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Italy: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Spain: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Russia: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. Rest of Europe: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 25. Growth Strategies in Europe Lung Cancer Therapy Market